These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 20846503)

  • 21. Recovery from cisplatin-induced ototoxicity: a case report and review.
    Truong MT; Winzelberg J; Chang KW
    Int J Pediatr Otorhinolaryngol; 2007 Oct; 71(10):1631-8. PubMed ID: 17706797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Monitoring hearing during ototoxic cisplatin therapy].
    Kluba J; Kluba U; von Specht H; Mittler U
    Padiatr Grenzgeb; 1990; 29(1):19-23. PubMed ID: 2342815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study.
    Moke DJ; Luo C; Millstein J; Knight KR; Rassekh SR; Brooks B; Ross CJD; Wright M; Mena V; Rushing T; Esbenshade AJ; Carleton BC; Orgel E
    Lancet Child Adolesc Health; 2021 Apr; 5(4):274-283. PubMed ID: 33581749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinically accurate assessment and grading of ototoxicity.
    Chang KW
    Laryngoscope; 2011 Dec; 121(12):2649-57. PubMed ID: 22109766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Ototoxicity of cisplatin chemotherapy in patients with ovarian cancer].
    Beck E; Schuster M; Berg A; Jäger W; Wildt L; Lang N
    Gynakol Rundsch; 1991; 31 Suppl 2():280-5. PubMed ID: 1790954
    [No Abstract]   [Full Text] [Related]  

  • 26. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
    Biró K
    Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose.
    Li Y; Womer RB; Silber JH
    Eur J Cancer; 2004 Nov; 40(16):2445-51. PubMed ID: 15519518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics of sensorineural hearing loss in children with inner ear anomalies.
    Coticchia JM; Gokhale A; Waltonen J; Sumer B
    Am J Otolaryngol; 2006; 27(1):33-8. PubMed ID: 16360821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ototoxic impact of cisplatin in pediatric oncology patients.
    Berg AL; Spitzer JB; Garvin JH
    Laryngoscope; 1999 Nov; 109(11):1806-14. PubMed ID: 10569412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sensorineural hearing loss in pediatric celiac patients.
    Hizli S; Karabulut H; Ozdemir O; Acar B; Abaci A; Dağli M; Karaşen RM
    Int J Pediatr Otorhinolaryngol; 2011 Jan; 75(1):65-8. PubMed ID: 21067821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.
    Knight KR; Kraemer DF; Winter C; Neuwelt EA
    J Clin Oncol; 2007 Apr; 25(10):1190-5. PubMed ID: 17401008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec.
    Peleva E; Emami N; Alzahrani M; Bezdjian A; Gurberg J; Carret AS; Daniel SJ
    Pediatr Blood Cancer; 2014 Nov; 61(11):2012-7. PubMed ID: 24976616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hearing loss caused by high dose carboplatin therapy].
    Lautermann J; Adamczyk M; ten Cate WJ; Kloke O
    Laryngorhinootologie; 1998 Feb; 77(2):82-4. PubMed ID: 9555700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.
    Langer T; Clemens E; Broer L; Maier L; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Mayer B; von dem Knesebeck A; Byrne J; van Dulmen-den Broeder E; Crocco M; Grabow D; Kaatsch P; Kaiser M; Spix C; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Bielack S; Sorg B; Hecker-Nolting S; Kuehni CE; Ansari M; Kompis M; van der Pal H; Parfitt R; Deuster D; Matulat P; Tillmanns A; Tissing WJE; Beck JD; Elsner S; Am Zehnhoff-Dinnesen A; van den Heuvel-Eibrink MM; Zolk O;
    Eur J Cancer; 2020 Oct; 138():212-224. PubMed ID: 32905960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
    Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
    J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives.
    Dhooge I; Dhooge C; Geukens S; De Clerck B; De Vel E; Vinck BM
    Int J Audiol; 2006 Jun; 45(6):337-43. PubMed ID: 16777780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected.
    Schmidt CM; Knief A; Lagosch AK; Deuster D; am Zehnhoff-Dinnesen A
    Ear Hear; 2008 Dec; 29(6):830-7. PubMed ID: 18772725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Asymmetric sensorineural hearing loss is a risk factor for late-onset hearing loss in pediatric cancer survivors following cisplatin treatment.
    Robertson MS; Hayashi SS; Camet ML; Trinkaus K; Henry J; Hayashi RJ
    Pediatr Blood Cancer; 2019 Jan; 66(1):e27494. PubMed ID: 30334605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of symptom control in patients with cancer in Northwestern Turkey.
    Kurt S; Unsar S
    Eur J Oncol Nurs; 2011 Apr; 15(2):137-44. PubMed ID: 20832359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cisplatin-induced hearing loss: the need for a long-term evaluating system.
    Yasui N; Adachi N; Kato M; Koh K; Asanuma S; Sakata H; Hanada R
    J Pediatr Hematol Oncol; 2014 May; 36(4):e241-5. PubMed ID: 24072246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.